Core Points - The company is Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd, established in 1993 and registered in Jilin Province, China [4][6][7] - The company aims to build a health industry chain and ecosystem, contributing to the modernization and internationalization of the national health industry while maximizing shareholder returns [9] - The registered capital of the company is RMB 966,494,707 [7] Chapter Summaries Chapter 1: General Principles - The company is established to protect the rights of shareholders, employees, and creditors, following the Company Law and Securities Law of the People's Republic of China [4] - The company has undergone several changes in its registration and licensing, including a name change to Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd in 2000 [6][7] Chapter 2: Business Objectives and Scope - The business objectives include serving human health and contributing to the health industry [9] - The business scope includes manufacturing various pharmaceutical forms, research and development of traditional Chinese medicine, and medical project investments [9] Chapter 3: Shares - The company issues shares in the form of stocks, with a total of 966,494,707 shares issued, all being ordinary shares [10][21] - The company follows principles of fairness and transparency in share issuance [10] Chapter 4: Shareholders and Shareholder Meetings - Shareholders have rights to dividends, attend meetings, and supervise company operations [16] - The company must hold annual shareholder meetings within six months after the end of the fiscal year [25] Chapter 5: Board of Directors - The board of directors is responsible for the company's management and must act in the best interest of the company and its shareholders [18] - The company has provisions for independent directors and committees within the board [18] Chapter 6: Senior Management - Senior management includes the general manager, deputy general managers, and other key personnel [8] Chapter 7: Financial Accounting System, Profit Distribution, and Auditing - The company must adhere to a financial accounting system and undergo internal audits [8] Chapter 8: Notices and Announcements - The company is required to issue notices and announcements as per legal requirements [8] Chapter 9: Mergers, Divisions, Capital Increases, Reductions, Dissolution, and Liquidation - The company can merge, divide, increase or reduce capital, and dissolve according to legal procedures [8] Chapter 10: Amendments to the Articles - The company can amend its articles of association following the prescribed procedures [8] Chapter 11: Supplementary Provisions - The articles of association serve as a binding document for the company, shareholders, directors, and senior management [8]

General Principles - The rules aim to clarify the responsibilities and authority of the board of directors of Tonghua Jinma Pharmaceutical Group Co., Ltd, ensuring efficient decision-making and compliance with relevant laws and regulations [1][2][3] Board of Directors - The board is a permanent institution responsible for the company's development goals and major operational decisions, accountable to the shareholders' meeting [2][3] - Directors must be natural persons and cannot hold office under certain disqualifying conditions, such as criminal convictions or bankruptcy responsibilities [4][5] - Directors are elected by the shareholders' meeting for a term of three years and may be re-elected [3][6] Duties and Obligations - Directors have a duty of loyalty to the company, which includes avoiding conflicts of interest and not misappropriating company assets [6][7] - Directors must act diligently and in the best interest of the company, ensuring compliance with laws and regulations [7][8] Board Composition and Powers - The board consists of nine directors, including three independent directors, and is led by a chairman [7][8] - The board has the authority to convene shareholder meetings, formulate profit distribution plans, and make significant operational decisions [8][9] Board Meetings - The board must hold at least two meetings annually, with specific procedures for calling and conducting meetings [12][13] - Decisions require a majority vote from attending directors, and independent directors have specific voting rights in related party transactions [14][15] Secretary of the Board - The company appoints a secretary responsible for coordinating information disclosure and managing investor relations [10][11] - The secretary must possess relevant professional knowledge and is accountable for maintaining confidentiality regarding company secrets [10][11] Record Keeping - The board must maintain detailed records of meetings, including attendance, agenda items, and voting results, which are preserved for at least ten years [17][18]

通化金马药业集团股份有限公司 章 程 （2025 年 6 月 23 日经公司 2024 年年度股东大会审议通过） 2025 年 6 月 — 1 — 目 录 — 2 — 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东会 第一节 股东的一般规定 第二节 控股股东和实际控制人 第三节 股东会的一般规定 第四节 股东会的召集 第五节 股东会的提案与通知 第六节 股东会的召开 第七节 股东会的表决和决议 第五章 董事和董事会 第一节 董事的一般规定 第二节 董事会 第三节 独立董事 第四节 董事会专门委员会 第六章 高级管理人员 第七章 财务会计制度、利润分配和审计 — 3 — 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第八章 通知和公告 第一节 通知 第二节 公告 第九章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十章 修改章程 第十一章 附则 第一章 总则 第一条 为维护本公司、股东、职工和债权人的合法权益，规范公司的组织和行 为，根据《中华人民共和国公司法》 ...

通化金马药业集团股份有限公司 股东会议事规则 （2025 年 6 月 23 日经公司 2024 年年度股东大会审议通过） 第一章 总则 第一条 为规范通化金马药业集团股份有限公司(以下简称"公司")的行为， 保证股东依法行使职权，维护股东的合法权益，根据《中华人民共和国公司法》 (以下简称"《公司法》")《通化金马药业集团股份有限公司章程》(以下简称 "《公司章程》")及其他有关法律、法规、规范性文件之规定制定本规则。 第二条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定 召开股东会,保证股东能够依法行使权利。 公司董事会应当切实履行职责,认真、按时组织股东会。公司全体董事应当 勤勉尽责,确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次, 应当于上一会计年度结束后的 6 个月内举行。临时股东会不定期召开,出现《公 司法》第一百一十三条规定的应当召开临时股东会的情形时,临时股东会应当在 2 个月内召开。 公司在上述期限内不能召开股东会的,应当报告公司所在地中国证券监督管 理委员会 ...

通化金马药业集团股份有限公司 董事会议事规则 （2025 年 6 月 23 日经公司 2024 年年度股东大会审议通过） 第一章 总则 第一条 为明确通化金马药业集团股份有限公司（以下简称"公司"）董事 会的职责权限，规范董事会的组织和行为，确保董事会的工作效率和科学决策， 根据《中华人民共和国公司法》（以下简称"公司法"）、《上市公司治理准则》、 《深圳证券交易所股票上市规则》和《通化金马药业集团股份有限公司章程》（以 下简称"公司章程"）的规定，制定本规则。 第二条 董事会是公司的常设机构，维护公司和全体股东的利益，负责公司 发展目标和重大经营活动的决策。 （六）被中国证监会采取证券市场禁入措施，期限未满的； 第三条 董事会对股东会负责，执行股东会决议。 第二章 董事 第四条 公司董事为自然人，有下列情形之一的，不能担任公司的董事： （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩序， 被判处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾 5 年，被宣告缓刑的， 自缓刑考验期满之日起未逾 2 年； （三）担任破产清算的公司、企业的董事或者厂长、经理 ...

证券代码：000766 证券简称：通化金马 公告编号：2025-29 通化金马药业集团股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会无否决提案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召开时间： 现场会议召开时间为：2025年6月23日下午14:30 网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年6月23日9:15—9:25，9:30—11:30和13:00—15:00；通过互联网投票系统 进行网络投票的具体时间为2025年6月23日上午9:15至下午15:00期间的任意时 间。 2、召开地点：吉林省通化市二道江区金马路999号，公司七楼会议室。 3、召开方式：采用现场表决与网络投票相结合的方式召开 4、召集人：公司董事会 5、现场会议主持人：董事长张玉富先生 6、会议召开的合法、合规性：本次会议的召集、召开与表决程序符合《公 司法》《上市公司股东会规则》《深圳证券交易所股票上市规则》等有关法律、行 政法 ...

吉林秉责律师事务所 关于通化金马药业集团股份有限公司 二 0 二四年年度股东大会的法律意见书 致：通化金马药业集团股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国 公司法》（以下简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股东会 规则》"）和《通化金马药业集团股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，吉林秉责律师事务所（以下简称"本所"）接受了通化金马药业集 团股份有限公司（以下简称"公司"）的委托，担任公司 2024 年年度股东大会（以 下简称"本次股东大会"）特聘专项法律顾问并出具法律意见书。 本法律意见书仅供公司为本次股东大会之目的而使用，不得用于其他任何目 的。本所同意公司将本法律意见书作为本次股东大会的公告材料，随其他需要公 告的信息一起向公众披露，并依法对本所在其中发表的法律意见承担责任。 为出具本法律意见书，本所指派郭淑芬、王红律师出席了公司于 2025 年 6 月 23 日下午 14 点 30 分在公司七楼会议室召开的本次股东大会，审查了公司提 供的召开本次股东大会有关的文件和资料，并进行了验证。在此基础上，本所按 照律师行 ...

Group 1 - The A-share innovative drug concept experienced a decline in early trading, with Changshan Pharmaceutical rapidly dropping to the daily limit [1] - Hanyu Pharmaceutical fell over 10%, indicating a significant downturn in the sector [1] - Other companies such as Tonghua Golden Horse, Guangsheng Tang, and Shutaishen also followed the downward trend [1]

证券代码：000766 证券简称：通化金马 公告编号：2025-28 通化金马药业集团股份有限公司 针对此次股票异常波动，公司董事会对公司自身情况进行了核查，并询问了 公司控股股东及实际控制人，现就有关情况说明如下： 1、公司前期披露的信息未发现需要更正、补充之处。 2、公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大 影响的未公开重大信息。 3、目前公司经营情况及内外部经营环境未发生重大变化。 4、公司、控股股东和实际控制人目前不存在关于本公司的应披露而未披露 的重大事项，或处于筹划阶段的重大事项。 5、股票异常波动期间，公司控股股东、实际控制人不存在买卖公司股票情 况。 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 通化金马药业集团股份有限公司（以下简称"公司"，证券简称：通化金马， 证券代码：000766）股票交易价格连续三个交易日（2025 年 6 月 12 日、6 月 13 日、6 月 16 日）日收盘价格涨幅偏离值累计超过 20%。根据深圳证券交易所的有 关规定，该情形属于股票交 ...

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][54]. Core Viewpoints - The report highlights that the AD (Alzheimer's Disease) treatment sector is expected to see significant advancements, with a recommendation to focus on companies like Tonghua Jinma and Dongcheng Pharmaceutical [3][9]. - The report emphasizes the importance of innovation, international expansion, and the aging population as key themes driving the industry forward [22][43]. - The pharmaceutical index has shown a positive performance, with a 1.40% increase from June 9 to June 13, outperforming the CSI 300 index by 1.66% [5][22]. Summary by Sections 1. AD Treatment Developments - The report notes that Alzheimer's Disease (AD) is a major global health challenge, with 51.62 million cases worldwide in 2019, including 13.14 million in China [9][10]. - The innovative oral drug, Succinyl-8-hydroxy-aminoguanidine, developed by Tonghua Jinma, has shown promising results in clinical trials and is expected to be a significant player in the AD treatment market [5][21]. 2. Industry Perspectives - The report indicates that the pharmaceutical sector is transitioning from traditional growth drivers to innovative solutions, with a focus on domestic innovation and international market expansion [22][43]. - The aging population is driving demand for chronic disease treatments, and the report suggests that the healthcare payment system is evolving to support this growth [41][43]. 3. Market Performance - The report provides a detailed analysis of stock performance, noting that 218 stocks increased in value while 263 decreased during the reporting period [5][22]. - Specific stocks such as Yiming Pharmaceutical and Sai Sheng Pharmaceutical have shown significant gains, while others like Renmin Tongtai have experienced notable declines [25][26]. 4. Investment Recommendations - The report recommends focusing on innovative pharmaceutical companies and those with strong international expansion capabilities, such as Heng Rui Pharmaceutical and Keren Pharmaceutical [43][44]. - It also highlights the importance of investing in sectors related to aging and outpatient consumption, suggesting companies like Kunming Pharmaceutical and Yuyue Medical [44].